Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage FDA Approval Rates: Niche Products Driving Record Success 

EP Vantage FDA Approval Rates

                                 

 

 

  Download EP Vantage FDA Approval Rates

Our latest report EP Vantage FDA Approval Rates: Niche Products Driving Record Success, shows that a focus on hard to treat  or specialist diseases is set to result in record post-launch sales for new drugs in 2013.

While the total tally of approved drugs and biologics for 2013 is not forecast to match last year’s record of 43, the combined US sales for this year’s approved products could surpass $18bn five years after launch. The report is based on market intelligence and analysis from EvaluatePharma and is the first in a new series of shorter reports from EP Vantage.

Key findings include:

  • Since January 1, to November 11, 2013, the FDA has approved 27 new compounds with another seven hopefuls awaiting approval.
  • Of the 27 drugs approved so far, combined fifth-year U.S. sales are forecast to reach $13.9bn.
  • Tecfidera ranks No. 1 among top five approvals of 2013 (January to November, 11) with sales estimated at $2.9bn by 2018.
  • If approved in 2013, Gilead Sciences’ sofosbuvir stands to become this year’s most valuable new molecule, with fifth-year US sales estimated at almost $3bn.

Download EP Vantage FDA Approval Rates

Press Release

Related Reports: 

EP Vantage Medtech Half-Year Review 2013

EP Vantage Pharma Half-Year Review 2013

EP Vantage 2012 Year in Review